Skip to main content
. 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261

Figure 3.

Figure 3

Median duration of adverse events experienced in the RECOURSE trial presented in (A) days and (B) proportion of the treatment period.